Impact Factor 4.416

Frontiers journals are at the top of citation and impact metrics

Perspective ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2018.00670

PARP inhibitors as sensitizer of Alkylation chemotherapy in Glioblastoma: impact of blood-brain barrier and molecular heterogeneity

  • 1Department of Radiation Oncology, Mayo Clinic, United States
  • 2Department of Radiation Oncology, Mayo Clinic, United States
  • 3Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, United States
  • 4Department of Oncology, Mayo Clinic, United States

Prognosis of patients with glioblastoma (GBM) remains dismal despite maximal surgical resection followed by aggressive chemo-radiation therapy. Almost every GBM, regardless of genotype, relapses as aggressive recurrent disease. Sensitization of GBM cells to chemo-radiation is expected to extend survival of patients with GBM by enhancing treatment efficacy. The PARP family of enzymes has a pleiotropic role in DNA repair and metabolism and has emerged as an attractive target for sensitization of cancer cells to genotoxic therapies. However, despite promising results from a number of preclinical studies, progress of clinical trials involving PARP inhibitors (PARPI) has been slower in GBM. Preclinical in vivo studies have uncovered limitations of PARPI mediated targeting of base excision repair, considered to be the mechanism of sensitization for temozolomide (TMZ)- resistant GBM. Nevertheless, PARPI remains a promising sensitizing approach for at least a subset of GBM tumors that are inherently sensitive to TMZ. Our PDX preclinical trial helped delineate MGMT promoter hyper-methylation as a biomarker of PARPI veliparib mediated sensitization. In clinical trials, MGMT promoter hyper-methylation now is being studied as a potential predictive biomarker not only for response to TMZ therapy alone, but also PARPI mediated sensitization of TMZ therapy. Besides the combination approach being investigated, IDH1/2 mutant gliomas associated with 2-hydroxygluterate mediated homologous recombination (HR) defect may potentially benefit from PARPI monotherapy. In this article, we discuss existing results and provide additional data in support of potential alternative mechanisms of sensitization that would help identify potential biomarkers for PARPI based therapeutic approaches to GBM.

Keywords: PARP (poly(ADP-ribose) polymerase, Chemo-radiation sensitivity, DNA Damage, replication stress, DNA repair activity

Received: 20 Nov 2018; Accepted: 19 Dec 2018.

Edited by:

Zhi Sheng, Virginia Tech, United States

Reviewed by:

Robin T. Varghese, Edward Via College of Osteopathic Medicine, United States
Thomas DAUBON, Institut National de la Santé et de la Recherche Médicale (INSERM), France  

Copyright: © 2018 Gupta, Smith, Tuma, Tian, Decker, Kizilbash, Kitange and Sarkaria. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Shiv K. Gupta, Mayo Clinic, Department of Radiation Oncology, Rochester, 55905, MN, United States, Gupta.Shiv@mayo.edu